Intravitreal aflibercept appears more beneficial in DME with serous retinal detachment

In the first 3 months of anti-VEGF therapy in patients with treatment-naive diabetic macular edema (DME) with serous retinal detachment (SRD), intravitreal aflibercept appears to be the more useful option, particularly in regard to the reduction of central retinal thickness (CRT) and SRD height, according to a study. After 6...

Read More